Overview

A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination With Nivolumab in Participants With Relapsed/Refractory Small Cell Lung Cancer

Status:
NOT_YET_RECRUITING

Trial end date:
2029-04-24

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the safety and tolerability of BMS-986525 alone and in combination with Nivolumab in participants with Relapsed/Refractory Small Cell Lung Cancer

Phase:

PHASE1

Details

Lead Sponsor:

Bristol-Myers Squibb

Treatments:

Nivolumab